What is the PREDiCT Series?
PREclinical Disease Modeling for Clinical Translation
Advancing Your Drug Candidate from Preclinical Stage to Clinic with Confidence & Bring Innovative Drugs to Patients Faster
The events within the PREDiCT Series focus on supporting drug developers in accelerating their innovative therapeutic pipeline to market, by bringing the preclinical community together to share, discuss and collaborate on how to advance preclinical studies.
Through novel technology adoption (from computation programs, to animal models, to better imaging modalities) our community discover the different approaches they can take to arm their translational decisions, enabling them to have a better understanding of candidate and the confidence to enter clinical trials knowing it is safe and effective.
The core questions to be answered at every PREDiCT meeting:
- What new model and additive technology initiatives are helping biopharma leaders drive translational and early-stage decision making?
- How do biopharma leaders balance advances in model complexity and relevance with the cost-per-data-point?
- What are the key criteria the leading biotech and pharma use to assess, select and characterise the array of tumour models